Outsourcing

Aging populations and increased access to healthcare translates into opportunities for biopharmaceutical companies.

Today’s analytical laboratory equipment reflects the realities of downsizing, outsourcing, and the need for speed.

Keith Moore, vice-president of analytical services, Metrics Contract Services discusses gains use in dissolution testing.

Today’s analytical laboratory equipment reflects the realities of downsizing, outsourcing, and the need for speed.

Novasep is building a new synthesis laboratory and adding capacity for kilogram-scale batches of synthetic molecules that are needed for biological testing and preclinical trials, at its Pennsylvania, US facility.

Vetter announces completion of multi-functional building for development service and IT functions.

Planned expansion at Onyx Scientific add laboratories, GMP suites, and storage space.

Charles River Laboratories entered into a definitive agreement to acquire WIL Research.

Takeda Pharmaceuticals announced the acquisition of a biopharmaceuticals manufacturing plant in Minnesota.

Industry experts discuss what the outsourcing market holds for 2016.

GENEWIZ signs definitive agreement to acquire Beckman Coulter's gene services business.

AMRI adds analytical capabilities to its outsourcing services offerings with the acquisition of Whitehouse Labs.

Quotient Clinical announced on Dec. 16, 2015 that is has acquired Co-Formulate Limited.

Capsugel adds clinical trial and commercial manufacturing, as well as particle engineering services with two acquisitions.

Grand River Aseptic Manufacturing expands disposable technology capabilities at aseptic facility.

Ajinomoto Althea expands biological drug product manufacturing operations to include ADCs.

Ropack Inc. adds R&D, formulation, lab analysis, and manufacturing capabilities in Long Island, NY.

Paragon Bioservices entered into a contract with the International Aids Vaccine Initiative for the process and analytical development and cGMP manufacturing of an HIV vaccine candidate.

CMO industry consolidation may be frustrated by a dearth of attractive assets.

As 3-D screening and lab automation improve lead optimization, open collaborative models are breaking down long-established walls. Will the industry redefine the way it handles R&D?

Ash Stevens has received FDA’s approval to manufacture Takeda’s multiple myeloma drug, ixazomib, at its facility in Riverview, Michigan.

The University of Sheffield has appointed Cobra Biologics to advance novel fusion protein technology into Phase 1 clinical trials.

Expansions at Catalent’s Kansas City, MO, and Madison, WI facilities made in response to industry demand.

Operations at Catalent’s Beinheim, France, softgel facility were suspended following suspected deliberate action to misplace capsules.

The UK’s National Biologics Manufacturing Centre will use Novasep’s BioSC Lab for protein purification.